AngioGenex, Inc. (AGGX) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
425 MADISON AVENUE, SUITE 902 NEW YORK, NY 10017 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 95,377 | 19,583 | 117,341 | 251,382 | 380,882 | 493,676 | |||
| Cash and cash equivalents | 95,377 | 19,583 | 117,341 | 251,382 | 380,882 | 493,676 | |||
| Prepaid expense | 24,281 | 33,236 | 31,245 | 3,995 | 12,864 | 21,634 | |||
| Total current assets: | 119,658 | 52,819 | 148,586 | 255,377 | 393,746 | 515,310 | |||
| Noncurrent Assets | |||||||||
| TOTAL ASSETS: | 119,658 | 52,819 | 148,586 | 255,377 | 393,746 | 515,310 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 295,170 | 319,894 | 459,760 | 436,602 | 441,941 | 383,695 | |||
| Interest and dividends payable | 45,082 | 45,067 | 45,052 | 45,037 | 45,073 | 51,081 | |||
| Employee-related liabilities | 95,000 | 95,000 | 95,000 | 95,000 | 95,000 | ||||
| Accrued liabilities | 155,088 | 179,827 | 61,941 | 15,007 | 15,007 | ||||
| Other undisclosed accounts payable and accrued liabilities | 257,767 | 281,558 | 286,861 | 332,614 | |||||
| Debt | 128,750 | 128,750 | 128,750 | 128,750 | 138,750 | 138,750 | |||
| Due to related parties | 172,349 | 159,868 | 145,376 | 179,920 | 179,920 | ||||
| Other undisclosed current liabilities | 553,669 | 487,602 | 380,671 | 398,296 | 451,679 | 619,938 | |||
| Total current liabilities: | 1,149,938 | 1,096,114 | 1,114,557 | 1,143,568 | 1,212,290 | 1,142,383 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 27,450 | 27,450 | 27,450 | 27,450 | 27,450 | 27,450 | |||
| Due to related parties | 27,450 | 27,450 | 27,450 | 27,450 | 27,450 | 27,450 | |||
| Total noncurrent liabilities: | 27,450 | 27,450 | 27,450 | 27,450 | 27,450 | 27,450 | |||
| Total liabilities: | 1,177,388 | 1,123,564 | 1,142,007 | 1,171,018 | 1,239,740 | 1,169,833 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (1,057,730) | (1,070,745) | (993,421) | (915,641) | (845,994) | (654,523) | |||
| Common stock | 30,387 | 29,387 | 29,387 | 29,387 | 29,387 | 29,387 | |||
| Additional paid in capital | 6,502,879 | 5,911,585 | 5,903,242 | 5,900,391 | 5,881,829 | 5,892,359 | |||
| Accumulated deficit | (7,590,996) | (7,011,717) | (6,926,050) | (6,845,419) | (6,757,210) | (6,576,269) | |||
| Other undisclosed equity, attributable to parent | |||||||||
| Total equity: | (1,057,730) | (1,070,745) | (993,421) | (915,641) | (845,994) | (654,523) | |||
| Other undisclosed liabilities and equity | (90,000) | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 119,658 | 52,819 | 148,586 | 255,377 | 303,746 | 515,310 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (576,934) | (94,583) | (78,330) | (88,683) | (178,064) | (35,375) | ||
| Other operating income (expense), net (Other Expenses) | (2,345) | (2,230) | (2,301) | 1,526 | 2,877 | 27,885 | ||
| Other undisclosed operating income (loss) | 2,345 | (6,705) | 2,301 | 474 | (2,877) | (27,885) | ||
| Operating loss: | (576,934) | (103,518) | (78,330) | (86,683) | (178,064) | (35,375) | ||
| Interest and debt expense | 2,449 | 2,394 | 2,468 | 2,113 | 2,723 | 27,779 | ||
| Loss from continuing operations before income taxes: | (574,485) | (101,124) | (75,862) | (84,570) | (175,341) | (7,596) | ||
| Other undisclosed loss from continuing operations | (11,146) | |||||||
| Loss from continuing operations: | (574,485) | (112,270) | (75,862) | (84,570) | (175,341) | (7,596) | ||
| Loss before gain (loss) on sale of properties: | (574,485) | (112,270) | (75,862) | (84,570) | (175,341) | (7,596) | ||
| Net loss: | (574,485) | (112,270) | (75,862) | (84,570) | (175,341) | (7,596) | ||
| Other undisclosed net income (loss) attributable to parent | (4,794) | 26,603 | (4,769) | (3,639) | (5,600) | (55,664) | ||
| Net loss available to common stockholders, diluted: | (579,279) | (85,667) | (80,631) | (88,209) | (180,941) | (63,260) | ||
Comprehensive Income (USD)Annual | Quarterly
| 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (574,485) | (112,270) | (75,862) | (84,570) | (175,341) | (7,596) | ||
| Comprehensive loss, net of tax, attributable to parent: | (574,485) | (112,270) | (75,862) | (84,570) | (175,341) | (7,596) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.